Inventiva Secures $10 Million Milestone Payment with CTTQ
Inventiva Announces Major Milestone Payment
Recently, Inventiva, a clinical-stage biopharmaceutical company, celebrated an important achievement by receiving a $10 million milestone payment from CTTQ. This payment marks a significant development in their licensing and collaboration agreement designed to expand the reach of their innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH).
Milestone Payment Details
This milestone payment is a direct response to the successful settlement of the second tranche of structured financing, which totals €115.6 million. The structured financing aims to strengthen Inventiva's operational capabilities and accelerate the development of its drug candidate lanifibranor.
Collaboration with CTTQ
The collaboration with CTTQ is particularly noteworthy. This agreement, initially established in September 2022 and later amended, empowers CTTQ with the rights to develop and commercialize lanifibranor across the Greater China region. Under this agreement, Inventiva could secure up to an additional $265 million in milestone payments, along with royalties based on future sales, should the product gain regulatory approval.
Regulatory Designations and Clinical Trials
Lanifibranor, Inventiva's flagship product, was granted Breakthrough Therapy Designation by regulatory bodies, a move that indicates its potential to expedite the drug development process. Following successful trials, this designation enhances the therapeutic possibilities for patients suffering from MASH and other metabolic conditions.
Potential for Market Approval
CTTQ is actively involved in the ongoing NATiV3 pivotal Phase 3 clinical trial for lanifibranor, which encompasses over 60 clinical sites in mainland China. The completion of Phase I bridging studies suggests no significant ethnic differences that could impede the path to regulatory approval in the region, further solidifying the partnership’s potential.
About Inventiva
Inventiva thrives on innovation, developing oral small molecule therapies targeting significant health disorders, including MASH. They are currently in the midst of extensive clinical trials to gather data and feedback to ensure their therapies meet stringent health regulations.
Exploring Future Opportunities
As a public company listed on the Euronext Paris and Nasdaq, Inventiva is positioned to lead advancements in biopharmaceutical treatments. The ongoing development of lanifibranor not only underscores their commitment to tackling metabolic diseases but also showcases their potential to create meaningful impact within the healthcare landscape.
Company Contacts
Inventiva
Pascaline Clerc
EVP, Strategy and Corporate Affairs
Email: media@inventivapharma.com
Phone: +1 202 499 8937
Brunswick Group
Tristan Roquet Montegon / Aude Lepreux / Julia Cailleteau
Email: inventiva@brunswickgroup.com
Phone: +33 1 53 96 83 83
ICR Healthcare
Patricia L. Bank
Email: patti.bank@icrhealthcare.com
Phone: +1 415 513 1284
Frequently Asked Questions
What is the significance of the $10 million payment?
This payment reflects Inventiva's successful progress in its collaboration with CTTQ regarding the development of lanifibranor.
What is lanifibranor?
Lanifibranor is an oral therapeutic candidate focused on treating metabolic dysfunction-associated steatohepatitis (MASH).
How does the Breakthrough Therapy Designation affect lanifibranor?
This designation speeds up the development and review process for lanifibranor, enhancing its chance for timely market approval.
What are future milestones for Inventiva?
Inventiva has the potential to receive additional milestone payments totaling $265 million based on the success of lanifibranor.
Where can I find more information about Inventiva?
For more details, you can visit Inventiva's official website or reach out through the provided contact information.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
